PDS Biotech Logo.png
PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022
October 05, 2022 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 05, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®
October 03, 2022 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 23, 2022 16:05 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 23, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech to Participate at Cantor Fitzgerald’s Oncology & HemOnc Conference
September 22, 2022 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
September 21, 2022 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech Logo.png
PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
August 24, 2022 16:01 ET | PDS Biotechnology Corporation
Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT FLORHAM PARK,...
PDS Biotech Logo.png
PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update
August 08, 2022 07:00 ET | PDS Biotechnology Corporation
Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology...
PDS Biotech Logo.png
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
August 04, 2022 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech Logo.png
PDS Biotech to Participate at BTIG Biotechnology Conference 2022
August 02, 2022 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...